JP7206223B2 - パーキンソン病の予防および／または支持治療処置のための物質 - Google Patents
パーキンソン病の予防および／または支持治療処置のための物質 Download PDFInfo
- Publication number
- JP7206223B2 JP7206223B2 JP2019571280A JP2019571280A JP7206223B2 JP 7206223 B2 JP7206223 B2 JP 7206223B2 JP 2019571280 A JP2019571280 A JP 2019571280A JP 2019571280 A JP2019571280 A JP 2019571280A JP 7206223 B2 JP7206223 B2 JP 7206223B2
- Authority
- JP
- Japan
- Prior art keywords
- butyric acid
- propionic acid
- physiologically acceptable
- disease
- parkinson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000126 substance Substances 0.000 title claims description 33
- 208000018737 Parkinson disease Diseases 0.000 title claims description 22
- 230000000069 prophylactic effect Effects 0.000 title claims description 8
- 230000003319 supportive effect Effects 0.000 title claims description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 64
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 31
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 26
- 235000019260 propionic acid Nutrition 0.000 claims description 25
- 239000002775 capsule Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 159000000007 calcium salts Chemical class 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000009117 preventive therapy Methods 0.000 claims 1
- 238000009120 supportive therapy Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 13
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 244000005700 microbiome Species 0.000 description 5
- 244000005709 gut microbiome Species 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/05—Propionic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017115819.7 | 2017-07-13 | ||
| DE102017115819.7A DE102017115819A1 (de) | 2017-07-13 | 2017-07-13 | Mittel zur prophylaktischen und/oder unterstützenden therapeutischen Behandlung von Morbus Parkinson |
| PCT/EP2018/069089 WO2019012108A1 (de) | 2017-07-13 | 2018-07-13 | Propion- und/oder buttersäure zur verwendung zur prophylaktischen und/oder unterstützenden therapeutischen behandlung von morbus parkinson |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526485A JP2020526485A (ja) | 2020-08-31 |
| JP2020526485A5 JP2020526485A5 (enExample) | 2021-02-04 |
| JP7206223B2 true JP7206223B2 (ja) | 2023-01-17 |
Family
ID=63108510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571280A Active JP7206223B2 (ja) | 2017-07-13 | 2018-07-13 | パーキンソン病の予防および／または支持治療処置のための物質 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200163914A1 (enExample) |
| EP (1) | EP3651754B1 (enExample) |
| JP (1) | JP7206223B2 (enExample) |
| KR (1) | KR20200027976A (enExample) |
| CN (1) | CN110996933A (enExample) |
| AU (2) | AU2018298862A1 (enExample) |
| BR (1) | BR112020000570A2 (enExample) |
| CA (1) | CA3067728A1 (enExample) |
| DE (1) | DE102017115819A1 (enExample) |
| WO (1) | WO2019012108A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021048440A1 (en) | 2019-09-13 | 2021-03-18 | Basf Se | Composition for the treatment of neurodegenerative diseases |
| CN111450238A (zh) * | 2020-03-31 | 2020-07-28 | 上海交通大学医学院附属瑞金医院 | 骨钙素或丙酸在制备抗帕金森病药物中的应用 |
| CN113332266A (zh) * | 2021-06-10 | 2021-09-03 | 徐州医科大学 | 含丁酸的治疗与预防神经退行性疾病的药物及丁酸的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016530239A (ja) | 2013-07-09 | 2016-09-29 | ピュアテック ベンチャーズ、エルエルシー | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
| WO2017067681A1 (de) | 2015-10-19 | 2017-04-27 | Flexopharm Brain Gmbh & Co. Kg | Mittel zur unterstützenden immunmodulation |
| WO2017091072A1 (en) | 2015-11-27 | 2017-06-01 | Birrbeheer B.V. | Butyrate salts for use in inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19503598A1 (de) * | 1995-02-03 | 1996-08-08 | Zuzana Dr Cully | Verfahren zur fermentativen Herstellung von Propionsäure oder Buttersäure bzw. deren Salze |
| NL1009990C2 (nl) * | 1998-09-02 | 2000-03-15 | Sibeco Chemicals | Voedingssupplement en werkwijze voor het vervaardigen van zulk voedingssupplement. |
| US20060105962A1 (en) * | 2004-11-14 | 2006-05-18 | Robinson Robert O A | Tonic to maintain intestinal flora |
| WO2012095461A1 (de) * | 2011-01-12 | 2012-07-19 | Albert Daxer | Getränk |
| CN105055457A (zh) * | 2015-08-06 | 2015-11-18 | 温州医科大学附属第二医院 | 一种防治阿尔茨海默病的药物及其制备方法和应用 |
| US11065217B2 (en) * | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
-
2017
- 2017-07-13 DE DE102017115819.7A patent/DE102017115819A1/de not_active Withdrawn
-
2018
- 2018-07-13 KR KR1020207003431A patent/KR20200027976A/ko not_active Ceased
- 2018-07-13 BR BR112020000570-3A patent/BR112020000570A2/pt not_active Application Discontinuation
- 2018-07-13 AU AU2018298862A patent/AU2018298862A1/en not_active Abandoned
- 2018-07-13 WO PCT/EP2018/069089 patent/WO2019012108A1/de not_active Ceased
- 2018-07-13 CN CN201880042374.6A patent/CN110996933A/zh active Pending
- 2018-07-13 US US16/627,688 patent/US20200163914A1/en not_active Abandoned
- 2018-07-13 EP EP18750103.6A patent/EP3651754B1/de active Active
- 2018-07-13 JP JP2019571280A patent/JP7206223B2/ja active Active
- 2018-07-13 CA CA3067728A patent/CA3067728A1/en active Pending
-
2021
- 2021-11-26 AU AU2021273627A patent/AU2021273627B2/en active Active
-
2022
- 2022-06-20 US US17/807,797 patent/US20220313634A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016530239A (ja) | 2013-07-09 | 2016-09-29 | ピュアテック ベンチャーズ、エルエルシー | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
| WO2017067681A1 (de) | 2015-10-19 | 2017-04-27 | Flexopharm Brain Gmbh & Co. Kg | Mittel zur unterstützenden immunmodulation |
| WO2017091072A1 (en) | 2015-11-27 | 2017-06-01 | Birrbeheer B.V. | Butyrate salts for use in inflammatory diseases |
Non-Patent Citations (1)
| Title |
|---|
| Neurochemistry International，2016年，Vol. 95，pp. 75-84 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200163914A1 (en) | 2020-05-28 |
| EP3651754A1 (de) | 2020-05-20 |
| DE102017115819A1 (de) | 2019-01-17 |
| KR20200027976A (ko) | 2020-03-13 |
| AU2021273627A1 (en) | 2021-12-16 |
| CA3067728A1 (en) | 2019-01-17 |
| BR112020000570A2 (pt) | 2020-07-14 |
| JP2020526485A (ja) | 2020-08-31 |
| CN110996933A (zh) | 2020-04-10 |
| WO2019012108A1 (de) | 2019-01-17 |
| US20220313634A1 (en) | 2022-10-06 |
| EP3651754C0 (de) | 2025-04-30 |
| AU2021273627B2 (en) | 2024-01-25 |
| EP3651754B1 (de) | 2025-04-30 |
| AU2018298862A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11471432B2 (en) | Supporting immunomodulatory agent | |
| US11865091B2 (en) | Supporting immunomodulatory agent | |
| AU2021273627B2 (en) | Agent for the prophylactic and/or supportive therapeutic treatment of Parkinson's disease | |
| TW200812567A (en) | Agent for improving nervous system cell functions | |
| EA025256B1 (ru) | Композиция, подходящая для лечения нарушений липидного обмена | |
| JP2017525771A (ja) | 体重と体脂肪減少に用いられる組成物およびその医薬品と使用 | |
| JP2007238441A (ja) | アスタキサンチンを有効成分とする体脂肪減少用組成物 | |
| CN106659729A (zh) | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物 | |
| US11304923B2 (en) | Use of a benzoate containing composition to treat glycine encephalopathy | |
| US11596166B2 (en) | Compositions and methods for treating aging and/or improving human health | |
| US8557236B2 (en) | Cardiovascular support supplement and compositions and methods thereof | |
| US20160114002A1 (en) | Compositions comprising plant proteins and methods for prevention of metabolic and cardiovascular pathologies in patient with cardiometabolic risk, including hyperglycemia | |
| US11458150B2 (en) | Methylphosphinic acid compositions and methods for reducing aging | |
| JP6594858B2 (ja) | メラトニン分泌調整剤、メラトニン分泌調整方法 | |
| JPWO2009054360A1 (ja) | 内臓脂肪特異的低減剤 | |
| US20180193312A1 (en) | Nutraceutical composition and dosing regimen | |
| TW201618767A (zh) | 治療不寧腿症候群及腿痙攣的組成物及方法 | |
| JPH02142732A (ja) | 肥満並びに肥満に関連する各種疾患の治療剤 | |
| CN120731089A (zh) | 末梢神经障碍的治疗或预防用医药品 | |
| CN102526088A (zh) | 维生素b12口服制剂的改进配方及用途 | |
| JP2009531306A5 (enExample) | ||
| JP2009173605A (ja) | 医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201215 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210915 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210921 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211221 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220311 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220715 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221206 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230104 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7206223 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |